{"name":"BioMarin Pharmaceutical","slug":"biomarin-pharmaceutical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"Vosoritide Injection","genericName":"Vosoritide Injection","slug":"vosoritide-injection","indication":"Other","status":"phase_2"},{"name":"BMN 111","genericName":"BMN 111","slug":"bmn-111","indication":"Achondroplasia (to increase adult height)","status":"phase_3"},{"name":"BMN 165","genericName":"BMN 165","slug":"bmn-165","indication":"Mucopolysaccharidosis IVA (Morquio A syndrome)","status":"phase_3"},{"name":"BMN 333","genericName":"BMN 333","slug":"bmn-333","indication":"Mucopolysaccharidosis type IIIB (MPS IIIB)","status":"phase_2"},{"name":"Placebo/rhASB","genericName":"Placebo/rhASB","slug":"placebo-rhasb","indication":"Maroteaux-Lamy syndrome (mucopolysaccharidosis VI)","status":"phase_3"},{"name":"BMN 110","genericName":"BMN 110","slug":"bmn-110","indication":"Tay-Sachs disease (late-infantile or juvenile onset)","status":"phase_3"},{"name":"N-acetylgalactosamine 4-sulfatase","genericName":"N-acetylgalactosamine 4-sulfatase","slug":"n-acetylgalactosamine-4-sulfatase","indication":"Morquio A syndrome (mucopolysaccharidosis IVA)","status":"phase_3"},{"name":"Phenoptin","genericName":"Phenoptin","slug":"phenoptin","indication":"Other","status":"phase_2"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"BMN 110 - Every Other Week","genericName":"BMN 110 - Every Other Week","slug":"bmn-110-every-other-week","indication":"Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)","status":"phase_3"},{"name":"BMN 110 - Weekly","genericName":"BMN 110 - Weekly","slug":"bmn-110-weekly","indication":"Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"RDD to Palynziq","genericName":"RDD to Palynziq","slug":"rdd-to-palynziq","indication":"Phenylketonuria (PKU) in patients with blood phenylalanine levels ≥600 μmol/L","status":"marketed"}]}],"pipeline":[{"name":"Vosoritide Injection","genericName":"Vosoritide Injection","slug":"vosoritide-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BMN 111","genericName":"BMN 111","slug":"bmn-111","phase":"phase_3","mechanism":"BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height.","indications":["Achondroplasia (to increase adult height)","Other skeletal dysplasias (under investigation)"],"catalyst":""},{"name":"BMN 165","genericName":"BMN 165","slug":"bmn-165","phase":"phase_3","mechanism":"BMN 165 is a gene therapy that delivers a functional copy of the GALNS gene to restore enzyme activity deficient in mucopolysaccharidosis IVA (Morquio A syndrome).","indications":["Mucopolysaccharidosis IVA (Morquio A syndrome)"],"catalyst":""},{"name":"BMN 333","genericName":"BMN 333","slug":"bmn-333","phase":"phase_2","mechanism":"BMN 333 is a small molecule that targets the enzyme alpha-N-acetylgalactosaminidase (NAGLU), which is deficient in patients with mucopolysaccharidosis type IIIB (MPS IIIB).","indications":["Mucopolysaccharidosis type IIIB (MPS IIIB)"],"catalyst":""},{"name":"Placebo/rhASB","genericName":"Placebo/rhASB","slug":"placebo-rhasb","phase":"phase_3","mechanism":"rhASB (recombinant human arylsulfatase B) is an enzyme replacement therapy that replaces deficient arylsulfatase B to break down glycosaminoglycans accumulated in Maroteaux-Lamy syndrome.","indications":["Maroteaux-Lamy syndrome (mucopolysaccharidosis VI)"],"catalyst":""},{"name":"BMN 110","genericName":"BMN 110","slug":"bmn-110","phase":"phase_3","mechanism":"BMN 110 is a gene therapy that delivers a functional copy of the HEXA gene to restore hexosaminidase A enzyme activity in patients with Tay-Sachs disease.","indications":["Tay-Sachs disease (late-infantile or juvenile onset)"],"catalyst":""},{"name":"BMN 110 - Every Other Week","genericName":"BMN 110 - Every Other Week","slug":"bmn-110-every-other-week","phase":"phase_3","mechanism":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.","indications":["Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)"],"catalyst":""},{"name":"BMN 110 - Weekly","genericName":"BMN 110 - Weekly","slug":"bmn-110-weekly","phase":"phase_3","mechanism":"BMN 110 is a recombinant human lysosomal acid lipase (LAL) enzyme replacement therapy that restores deficient enzyme activity in patients with LAL deficiency.","indications":["Lysosomal acid lipase (LAL) deficiency, including Wolman disease and cholesteryl ester storage disease (CESD)"],"catalyst":""},{"name":"N-acetylgalactosamine 4-sulfatase","genericName":"N-acetylgalactosamine 4-sulfatase","slug":"n-acetylgalactosamine-4-sulfatase","phase":"phase_3","mechanism":"N-acetylgalactosamine 4-sulfatase is an enzyme replacement therapy that replaces the deficient GALNS enzyme to break down keratan sulfate and chondroitin 6-sulfate in lysosomal storage disease.","indications":["Morquio A syndrome (mucopolysaccharidosis IVA)"],"catalyst":""},{"name":"Phenoptin","genericName":"Phenoptin","slug":"phenoptin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RDD to Palynziq","genericName":"RDD to Palynziq","slug":"rdd-to-palynziq","phase":"marketed","mechanism":"Palynziq is a recombinant phenylalanine ammonia-lyase (PAL) enzyme that breaks down phenylalanine, reducing blood phenylalanine levels in patients with phenylketonuria.","indications":["Phenylketonuria (PKU) in patients with blood phenylalanine levels ≥600 μmol/L"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPUFhUeXh4RkpYU3I3Uy02aWdLcm5TVl83ajJkdC0yTzZNV0xMUkJ1d0E5LUcyV3RqRWFXekRxQzZnV0JVVkgxS0ZRUkJXeEppakhqOWIxZ2dMSTRoTG9SV3M1QkhOYU15TUNpdHpHbEpxLXh4Z0thSjR4cnhWbkZtcEY0eFY3TEhhWEphTVYzd3hJQktMSUhxXzJmbkJ5TWNBV2VRS0VCb1ltOXJObThhNHhaUTNpT29Vb3YxUmkwc3dDSlgwR3lB?oc=5","date":"2026-03-16","type":"pipeline","source":"Fierce Pharma","summary":"BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma","headline":"BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPWFNLLWR2aktJMFEtWmZfMUNYSjA5MDM3dGNPQTRYMFRrYVg0V0ZLNWlXcHZOZXIyZW1Tbzh3czZqRWxvc1lSZjFTTXRHM0xhc21kMU5La3NZZEVmeTZBRW16YnlaSnJaMHV4TW1leUhiMHZHVWJvMHdFZDRyWENxc3NsWEcxclpSSkVj?oc=5","date":"2026-02-01","type":"pipeline","source":"seekingalpha.com","summary":"The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - seekingalpha.com","headline":"The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9hRWh3TFA2VkkxMk5KLVNZbmE0ekhuT2QxRkZha1czeTN5QlRsQ3NkcnVDallVWXQxSk1HQjBfMkd3SU5SRlZmVi1WaDNFejNBQWZr?oc=5","date":"2026-01-22","type":"pipeline","source":"FirstWord Pharma","summary":"Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D - FirstWord Pharma","headline":"Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPWkhmLWpqOUhBRTVmajZYU0FHNE5LdGRSY1dYTjRKM29oT1FUemRrWmFQakdQOTdYRXJUVDFjWjhTZkIzeE9RODZXbmIyQWgyamVlcldERVZsbkw5YnJJMTI0dUNqQzBGNU5FTmJMZjdPbTBCSVc3R1VYMUNXZ0pjTHRveVJQNEhsSzBIc1RJYnNwMVpsRWUtekJweFM2blVzclE?oc=5","date":"2026-01-22","type":"pipeline","source":"BioPharma Dive","summary":"BioMarin vets form Mendra to ‘modernize’ rare disease drug development - BioPharma Dive","headline":"BioMarin vets form Mendra to ‘modernize’ rare disease drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPQzBraWRKbHhKUVFES1FhTm8tYVlsd29WRHNlcEZSZ3VSMVN1WGZYVzhKSjBXMVNEY0hFZWxqRE1RWWduWDZEeU1DeGt1ZTlLRDlUdTFiQm5UZXNSR1FHeURGQ2hGMGVUdlBZQVJ6SThqM1hpZzlGQTROc0pTbkhXb1FCX3ZnTTZzNzItY1l6UmJGMTQ0N2hXN3B3?oc=5","date":"2025-12-29","type":"deal","source":"Contract Pharma","summary":"BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma","headline":"BioMarin to Acquire Amicus Therapeutics for $4.8B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVEdPSDRaVnFhT3kyUUdoVWM4SmEyOF9KSE5PWXByTDFKbjB1eld5aU1JZXpUZU9MQldSZU1EMDBkMGlXQk13cnk0QU8tUmg1dWZnMzBnMjV4em9tdk1VUWQzcVhWWTU4WldNQnVMM0h2ODhZMlNoUlpfeVZva1BTSDJISGJTZWtZOFU0bkpJLUNycUV0UVE2MHFOeDd4VlEzb2xkSWE2dlJncjQ?oc=5","date":"2025-12-26","type":"pipeline","source":"seekingalpha.com","summary":"BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - seekingalpha.com","headline":"BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNS1R6TmEzX3lqTmRaZXczdU1OcEtiTHhnaWZUZG0xaWl1MFJ4QV9GVnVEdkhFUE9YWDRXX0xTQThvYWtGRjFZdlVtRHBtMERWWVJQRmtCNWhZRE55dThQUjd6Znc4STNHMFBJQkFiRmpVZjdZY2p1czd3LUJJMDJMOWtqRjlDald1OWQ2WTlEWmJlODR0ZjI2cjAzNENnWmJoZmhCbU52aw?oc=5","date":"2025-12-22","type":"pipeline","source":"Pharmaceutical Technology","summary":"BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology","headline":"BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBrZVUzYndPRzcyY055TTFtYzdCWHhjNEIwNndRNHBuT180clNuZGYzMVYyeFVZUVlQWEx2ekMwRVZUSDIxRTI2cm1MSTlvLWNrNDJVckhvcnd3VGo3SDkxUkttSndYQlpjUVZYcHBiYW9Hamc?oc=5","date":"2025-12-22","type":"pipeline","source":"pharmaphorum","summary":"BioMarin ends year with $4.8bn play for Amicus - pharmaphorum","headline":"BioMarin ends year with $4.8bn play for Amicus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZTdHcTFtSEU2UmNucFZGdHlTNFN4aWlOeEVMdU9ycmVwR05DV0YtbjBXR0tlSnV6bnhoZ3JLWnlET1JJX25RMTBtejE4UVpZUDRfd2EwNE9UUEZmcy16SFlQSmxNRW9YX2pmLVI5TkRITXZwdWpTZlNMSnY2YXhYcTkzeVIwQ21IN0tkWDU0WmVTbzFyNW9Jd2FNU0NsRXl3VVg3U00zdUNGMWJLM1QxMUIwM3A?oc=5","date":"2025-12-19","type":"pipeline","source":"MedCity News","summary":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News","headline":"BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPOGRCZHpZQWt0SjBMWWh1UEpkSk9USWYyY25wLWlib1JpQjBCcEM2U0M1Z2VGY0txWFZ5aEVNYWE4ME43c1ZyRm84UmNfYUhDNU1sR0RFOFE4Wk14ZmlwOElRUzZMT1kxRS1YWkd5UEV4NzI3Vkc1dFNRVDBWbExCZm1WYzFqQkRIaHVOeFhTLUZoVi1BOHNnWHU0ZEVSR3I3X1pCSC1R?oc=5","date":"2025-12-19","type":"deal","source":"Reuters","summary":"BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet - Reuters","headline":"BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaFdYb2JKdUpKWW9BWTJxUDlDSmh1TGNpY0MxMmR6UVMxaTFEeEhjbWxXWG9vNEdZTHdWTTVyNjZHS1hDb1hBNmZSR1RQakZTUGRPY1BZU0xhR3hmN1lwcTAtMUhWbE51X1VKTWxzdFRTY1RLbXhHWnJyLUlLWEg3NDhCVVdMQ21wWHpQZXk0WDZMcGlUQ0RvTXBvLXVzcmhrMFFkY1pWSUFNUjUzQXBhVmNlTnR6VVVPcE44WEhCaXE?oc=5","date":"2025-08-01","type":"pipeline","source":"prnewswire.com","summary":"BioMarin Announces Appointment of Ian T. Clark to Board of Directors - prnewswire.com","headline":"BioMarin Announces Appointment of Ian T. Clark to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOV2FlU2I3aXgxTnF5VFhjMDJub1M1Nld1QTN2QkxNMlI3SGNpclh5ZlZGS2pTaTlJakotR21rN0tMclVEcVVoN3hETDRUdU8xdUVITk9MYW1nQjFjYksxOEpjNEtGRHY3cmpvWFdzV2lpRFByN01KT3pTNFNlUVFUUDFpN2JhOVIzOFNJbnIweTFUdlFLRUN6M3Y3R2k?oc=5","date":"2025-07-10","type":"pipeline","source":"Yahoo Finance","summary":"BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - Yahoo Finance","headline":"BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_2":3,"phase_3":7,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}